Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Mechanochemical Ablation Versus Ultrasound-Guided Foam Sclerotherapy of the Great Saphenous Vein

23 avril 2026 mis à jour par: Antonio Eduardo Zerati

Mechanochemical Ablation Versus Ultrasound-Guided Foam Sclerotherapy of the Great Saphenous Vein: Randomized Clinical Trial

This study compares two minimally invasive treatments for varicose veins in the legs, specifically the great saphenous vein.

Varicose veins can cause symptoms such as leg pain, swelling, and skin changes. One commonly used treatment is foam sclerotherapy, where a special foam is injected into the vein to close it. This method is simple and allows patients to return quickly to their daily activities, but sometimes the vein can reopen, requiring additional treatments.

Another option is mechanochemical ablation, which combines a small device with a medication to close the vein. This method also allows for quick recovery and may have a lower chance of the vein reopening.

In this study, 50 patients with varicose veins will be randomly assigned to receive one of these two treatments. Doctors will follow patients over time to evaluate:

How well the treated vein stays closed Improvement in quality of life Pain during the procedure Possible complications All procedures are performed with local anesthesia, and additional small varicose veins are treated at the same time.

Aperçu de l'étude

Description détaillée

Introduction:

Ultrasound-guided foam sclerotherapy is a widely used method for the treatment of lower limb varicose veins. Its main advantages include applicability in patients at high surgical risk and immediate or early return to daily activities. However, it requires a higher number of reinterventions compared to other techniques due to increased rates of venous recanalization, particularly in larger-caliber veins. In contrast, mechanochemical ablation shares these advantages and is associated with lower recanalization rates.

Objective:

To compare ultrasound-guided foam sclerotherapy of the great saphenous vein (GSV) with mechanochemical ablation using the Flebogrif® catheter in the treatment of chronic venous insufficiency (CVI) associated with GSV disease. The primary endpoints will be quality of life assessment and GSV occlusion rate, as determined by lower limb venous color Doppler ultrasonography over the proposed follow-up period. Secondary endpoints include the incidence of treatment-related complications and pain level during the procedure.

Patients and Methods:

A total of 50 patients with primary varicose veins will be selected. Inclusion criteria include lower limb pain, edema, or skin changes such as hyperpigmentation, eczema, and lipodermatosclerosis (CEAP classification C2-C4, EpAsPr), as well as GSV insufficiency with a diameter between 6 and 12 mm measured at the mid-thigh using color Doppler ultrasonography. Clinical evaluations and ultrasound examinations will be conducted at the venous disease outpatient clinic, and procedures will be performed in the minor surgery operating room of the University of São Paulo Hospital.

This will be a prospective randomized study, with patients allocated into two groups according to the treatment technique.

Group 1: Percutaneous puncture and ultrasound-guided injection of sclerosant foam through a short 18G catheter.

Group 2: Use of the Flebogrif® catheter, positioned under ultrasound guidance 2 cm from the saphenofemoral junction, followed by catheter withdrawal combined with sclerosant foam injection.

In both groups, 20 mL of 0.9% saline solution will be infused prior to polidocanol administration. The GSV puncture site will depend on the extent of insufficiency (segmental or total), being performed at the knee or medial malleolar region, respectively, after local anesthesia with 2% lidocaine without vasoconstrictor and without infiltration along the venous course.

For knee-level puncture, a tourniquet will be applied distal to the access site and maintained for 5 minutes after foam injection to prevent dispersion into healthy venous segments.

In all patients, varicose tributaries will be treated immediately after the GSV procedure using 1% polidocanol sclerotherapy.

Expected Results:

Mechanochemical ablation is expected to demonstrate a higher target vein occlusion rate with lower recanalization rates, without increased procedural pain and with at least a comparable complication rate to ultrasound-guided foam sclerotherapy. This study aims to contribute to the refinement of treatment strategies, seeking greater efficacy with monotherapy.

Type d'étude

Interventionnel

Inscription (Estimé)

50

Phase

  • Phase 4

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

  • Nom: Antonio Zerati, PhD
  • Numéro de téléphone: +5511996354925
  • E-mail: a.zerati@fm.usp.br

Lieux d'étude

    • São Paulo
      • São Paulo, São Paulo, Brésil
        • Recrutement
        • Hospital da Clínicas da FMUSP
        • Contact:
        • Chercheur principal:
          • Antonio Zerati, PhD

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

  • Adulte
  • Adulte plus âgé

Accepte les volontaires sains

Non

La description

Inclusion Criteria:

  • CEAP Classification C2, 3 or 4
  • Insufficient great saphenous vein measuring 6-12 mm in the mid-thigh on Doppler ultrasound.

Exclusion Criteria:

  • Allergy to sclerosing substances
  • Deep venous thrombosis, stroke, or pulmonary embolism
  • Local or generalized infection at the sclerotherapy site
  • Prolonged immobilization
  • Asymptomatic patent foramen ovale
  • Pregnancy Occlusive peripheral arterial disease

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Comparateur actif: Great saphenous vein insufficiency (1)
25 limbs with great saphenous vein insufficiency
Mechanical-chemical ablation is a technique for treating varicose veins that combines mechanical damage to the venous endothelium with chemical damage using polidocanol foam.
Polidocanol foam is a drug infused into varicose veins, causing chemical damage to the endothelium.
Expérimental: Great saphenous vein insufficiency (2)
25 limbs with great saphenous vein insufficiency
Mechanical-chemical ablation is a technique for treating varicose veins that combines mechanical damage to the venous endothelium with chemical damage using polidocanol foam.
Polidocanol foam is a drug infused into varicose veins, causing chemical damage to the endothelium.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Quality Of Life Score: Brazilian Version Adapted from the Aberdeen Varicose Veins Questionnaire
Délai: From enrollment to the end of treatment at 365 days after procedure
Brazilian Version Adapted from the Aberdeen Varicose Veins Questionnaire will be used. Score from 0 to 100, where 0 is the best and 100 is the worst quality of life related to varicose veins.
From enrollment to the end of treatment at 365 days after procedure
Disease Severity Score: Venous Clinical Severity Score (VCSS)
Délai: From enrollment to the end of treatment at 365 days after procedure
Venous Clinical Severity Score (VCSS) will be used. Score from 0 to 30, where 0 means asymptomatic patient and 30 means more symptomatic patient as possible.
From enrollment to the end of treatment at 365 days after procedure
Ultrasound Assessment: Classification of the Second European Consensus Meeting on Foam Sclerotherapy Held in Tegernsee, Germany in 2006
Délai: From enrollment to the end of treatment at 365 days after procedure
Classification of the Second European Consensus Meeting on Foam Sclerotherapy Held in Tegernsee, Germany in 2006, will be used. Classification where 0 means reflux greater than 1 second, 1 means reflux less than 1 second, and 2 means no reflux.
From enrollment to the end of treatment at 365 days after procedure

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Treatment complications
Délai: One to 365 after procedure
Deep vein thrombosis, thrombophlebitis, visual disturbances, skin irritation and skin hyperpigmentation.
One to 365 after procedure
Pain Level During Procedure: Visual Analog Pain Scale
Délai: Pain level during the procedure
Visual Analog Pain Scale will be used. Scale where 0 means no pain and 10 means maximum pain during procedure.
Pain level during the procedure

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

1 mai 2026

Achèvement primaire (Estimé)

1 août 2027

Achèvement de l'étude (Estimé)

1 novembre 2027

Dates d'inscription aux études

Première soumission

14 avril 2026

Première soumission répondant aux critères de contrôle qualité

23 avril 2026

Première publication (Réel)

1 mai 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

1 mai 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

23 avril 2026

Dernière vérification

1 avril 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • 83198024.0.0000.0068

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

INDÉCIS

Description du régime IPD

Undecided. Maybe after publication.

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

produit fabriqué et exporté des États-Unis.

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner